GPC3 and hepatocellular carcinoma: A phase I clinical trial (NCT02905188) is evaluating the feasibility of GPC3-specific CAR-T cells (GLYCAR T cells) in patients with advanced HCC, aiming to determine the maximum tolerated dose, persistence of infused cells, safety profile, and preliminary antitumour efficacy.